Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc/ US92532F1003 /
VRTX
|
2024-05-29 10:00:00 PM
|
Chg.
-5.7500
|
Volume |
Bid1:54:02 AM |
Ask1:54:02 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
441.1300USD
|
-1.29%
|
967,463
Turnover: 230.75 mill. |
433.1700Bid Size: 100 |
443.5600Ask Size: 100 |
113.84 bill.USD |
- |
31.40 |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
14.05 USD |
8.33% |
| EPS Diluted: |
13.89 USD |
8.35% |
| Revenues per Share: |
38.21 USD |
9.99% |
| Book Value per Share: |
68.06 USD |
25.77% |
| Cash Flow per Share: |
13.69 USD |
-14.75% |
| Dividend per Share: |
- USD |
- |
| Total |
in mill. |
|
| Revenues: |
9,869.20 USD |
10.51% |
| Net Income: |
3,619.60 USD |
8.96% |
| Operating Cash Flow: |
3,537.30 USD |
- |
| Cash and Cash Equivalents: |
10,369.10 USD |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
31.40 |
28.96 |
| P/S Ratio: |
11.55 |
10.65 |
| P/BV ratio: |
6.48 |
5.98 |
| P/CF Ratio: |
32.21 |
29.71 |
| PEG: |
3.77 |
3.48 |
| Earnings Yield: |
3.19% |
3.45% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
113.84 bill. USD |
105.1 bill. USD |
| Free Float Market Cap.: |
- USD |
- USD |
| Market Cap. / Employee: |
- USD |
- USD |
| Shares Outstanding: |
258.31 mill. |
|
Profitability
| Gross Profit Margin: |
87.21% |
| EBIT Margin: |
38.83% |
| Net Profit Margin: |
36.68% |
| Return on Equity: |
20.59% |
| Return on Assets: |
15.92% |
Financial Strength
| Liquidity I / Cash Ratio: |
292.30% |
| Liquidity II / Quick Ratio: |
336.37% |
| Liquidity III / Current Ratio: |
398.72% |
| Debt / Equity Ratio: |
29.29% |
| Dynam. Debt / Equity Ratio: |
145.59% |
Efficiency
| Employees: |
- |
| Personal Expenses / Employee: |
- USD |
| Revenues / Employee: |
- USD |
| Net Income / Employee: |
- USD |
| Total Assets / Employee: |
- USD |
| * Fiscal Year End: |
2023-12-31 |
| Accounting Standard: |
US GAAP |
